The efficacy of myo-inositol supplementation to reduce the incidence of gestational diabetes: a meta-analysis

Abstract

Introduction

Myo-inositol supplementation is used to reduce the incidence of gestational diabetes, but its efficacy is not well established. This meta-analysis aims to explore the influence of myo-inositol supplementation on the prevention of gestational diabetes.

Methods

This meta-analysis has been conducted up to March 2022 to identify randomized clinical trials comparing the efficacy of myo-inositol supplementation to prevent gestational diabetes. Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systemically.

Results

We have included eight RCTs in this meta-analysis. Compared with control group in pregnant women, myo-inositol supplementation was found to significantly decrease the incidence of gestational diabetes (OR = 0.40; 95% CI = 0.19 to 0.84; p = .01), 2-h glucose OGTT (SMD = −0.22; 95% CI = −0.41 to −0.02; p = .03), HOMA-IR (SMD = −0.25; 95% CI = −0.42 to −0.08; p = .004) and preterm delivery (OR = 0.41; 95% CI = 0.23 to 0.73; p = .003), but demonstrated no obvious impact on gestational age at birth (SMD = 0.12; 95% CI = −0.05 to 0.29; p = .18) or birth weight (SMD = −0.04; 95% CI = −0.20 to 0.13; p = .68).

Conclusions

Myo-inositol supplementation is effective to reduce the incidence of gestational diabetes, 2-h glucose OGTT, HOMA-IR and preterm delivery, which suggested that myo-inositol supplementation should be recommended to prevent gestational diabetes.

摘要

前言：肌醇补充用于降低妊娠期糖尿病的发病率, 但其疗效尚不明确。本荟萃分析旨在探讨补充肌醇对预防妊娠期糖尿病的影响。

方法：该荟萃分析已于2022年3月进行, 以确定比较肌醇补充对预防妊娠期糖尿病疗效的随机临床试验。对PubMed、EMbase、Web of science、EBSCO和Cochrane图书馆数据库等多个数据库进行了系统分析。

结果：我们在这项荟萃分析中纳入了8项随机对照试验。与孕妇对照组相比, 肌醇补充可显著降低妊娠期糖尿病的发生率（OR＝0.40；95%CI＝0.19至0.84；p＝.01）、2小时葡萄糖OGTT（SMD＝-0.22；95%CI＝-0.41至-0.02；p＝.03）、HOMA-IR（SMD＝-0.25；95%CI＝-0.42至-0.08；p＝.004）和早产（OR＝0.41；95%CI＝0.23至0.73；p＝.003）, 但对出生时的胎龄（SMD＝0.12；95%CI＝-0.05至0.29；p＝.18）或出生体重（SMD＝-0.04；95%CI＝-0.20至0.13；p＝.68）无明显影响。

结论：肌醇补充可有效降低妊娠期糖尿病、2小时葡萄糖OGTT、HOMA-IR和早产的发生率, 提示应推荐肌醇补充预防妊娠期糖尿病。

Keywords:

• Gestational diabetes
• myo-inositol supplementation
• randomized controlled trials
• meta-analysis

Disclosure statement

No potential conflict of interest was reported by the author(s).